Biodesix (NASDAQ:BDSX) Announces Earnings Results, Beats Estimates By $0.32 EPS

Key Points

• Biodesix reported $0.32 EPS beat, posting EPS of ($0.81) versus estimates of ($1.13) and revenue of $25.6 million (up ~42% YoY), while raising 2026 revenue guidance to $108–$114 million (≈25% growth at the midpoint).
• Profitability metrics improved as gross margin expanded to 84% GAAP (82% ex one‑time), adjusted EBITDA loss narrowed 35% to a $4.1 million loss, and net loss declined ~30%, signaling operating leverage toward sustained profitability.
• Diagnostic momentum continues with ~17,800 tests in Q1 (up ~29% YoY), primary care now ~15% of volumes, and an expanding field team, although management is reinvesting in commercial capacity which raises near‑term operating expenses.

Biodesix (NASDAQ:BDSX - Get Free Report) announced its earnings results on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.32, Zacks reports. The firm had revenue of $25.55 million during the quarter, compared to analyst estimates of $23.12 million. Biodesix had a negative net margin of 39.85% and a negative return on equity of 1,760.83%.

Here are the key takeaways from Biodesix's conference call:

• Biodesix reported first-quarter revenue of $25.6 million (up 42% YoY) and raised 2026 guidance to $108–$114 million, implying ~25% growth at the midpoint versus 2025.
• Gross margin expanded to 84% GAAP (82% ex one‑time benefit), adjusted EBITDA loss improved 35% to a $4.1 million loss and net loss narrowed 30%, signaling continued operating leverage and progress toward sustained profitability.
• Diagnostic momentum includes ~17,800 tests in Q1 (up 29% YoY) with primary care now ~15% of volumes and a field team of ~100 reps (adding ~6 reps/quarter); management expects volume-driven growth but is reinvesting in commercial capacity, which raises near‑term operating expense.
• Development services revenue nearly doubled to $3.3 million and the company exited the quarter with about $10.4 million in contracted backlog, reflecting sustained biopharma demand and multi‑omic differentiation.

Biodesix Stock Up 1.7%

NASDAQ:BDSX opened at $11.27 on Tuesday. The business's 50-day moving average price is $14.39 and its 200 day moving average price is $10.36. Biodesix has a 52-week low of $3.44 and a 52-week high of $20.21. The firm has a market cap of $113.94 million, a P/E ratio of -2.32 and a beta of 0.43.

Insiders Place Their Bets

In other news, CEO Scott Hutton sold 3,559 shares of the firm's stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer owned 45,413 shares in the company, valued at approximately $457,763.04. This trade represents a 7.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders have sold 9,052 shares of company stock valued at $100,227. 23.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Biodesix

A number of hedge funds and other institutional investors have recently made changes to their positions in BDSX. Geode Capital Management LLC grew its position in Biodesix by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock worth $289,000 after buying an additional 2,235 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Biodesix during the 4th quarter valued at $187,000. State Street Corp lifted its position in shares of Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company's stock valued at $121,000 after acquiring an additional 2,400 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Biodesix during the 3rd quarter worth $113,000. Finally, DRW Securities LLC bought a new stake in shares of Biodesix during the 4th quarter worth $105,000. 20.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. William Blair raised shares of Biodesix from a "market perform" rating to an "outperform" rating in a research note on Friday, February 27th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 target price on shares of Biodesix in a report on Tuesday, February 17th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Biodesix has a consensus rating of "Moderate Buy" and a consensus target price of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.